吉利德科学（GileadSciences）今日公布其每半年注射一次的艾滋病毒衣壳抑制剂lenacapavir用于预防艾滋病毒（HIV）感染的第二项关键3期试验PURPOSE ...

智通财经APP获悉，吉利德科学 (GILD.US) 今日公布其每半年注射一次的艾滋病毒衣壳抑制剂lenacapavir用于预防艾滋病毒 (HIV)感染的第二项关键3期试验PURPOSE ...

Gilead Sciences, Inc. (Nasdaq: GILD) today presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE ...

点击上方“感染学苑” 掌握感染疾病前沿动态新闻原名为《HIV 流行的终结是否即将到来？》，由哈佛特约撰稿人Alvin Powell撰写。新闻于2024年7月24日发布在《哈佛公报》上。这篇文章讨论了哈佛大学公共卫生学院的免疫学和传染病教授 Roger ...

The “Drop Pop” X account, a satirical parody account that looks similar to actual news accounts, is behind the false claims ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

What Truvada is, is a single pill that’s a combination of two antiretroviral drugs that have a long history of being used as part of a broader combination of therapy for the actual treatment of ...

The patent for branded TDF/emtricitabine (Truvada) has expired, allowing multiple manufacturers to offer inexpensive generic versions that contain the same ingredients. Branded TAF/emtricitabine ...

吉利德最新公布结果的是一项名为“PURPOSE 1”的三期双盲随机研究试验，旨在评估Lenacapavir、Descovy、Truvada对南非25个站点和乌干达3个站点的5300多名16 ...

Sciences presented the first in-depth look at full results from its pivotal Phase 3 PURPOSE 2 trial, which is studying ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Three years after the discovery of the human immunodeficiency virus (HIV) in 1984, GlaxoSmithKline's (GSK's) Retrovir (zidovudine) became the first drug to be approved for the treatment of this ...